BillionToOne, Inc. (NASDAQ: BLLN) reported a total revenue of $83.5 million in Q3 2025, up 117% from the previous year. Prenatal testing revenue was $74.1 million, a 102% increase, while oncology testing revenue was $8.7 million, a 7.6x increase. Gross margin was 70%, and operating income was $9.6 million.

BillionToOne’s innovative technology and execution led to a strong financial profile. The company expects full year 2025 revenue of $293-$299 million, a 92%-96% increase. Q4 2025 revenue is projected to be $84-$90 million, an 86%-100% increase. Positive operating income is expected for both Q4 2025 and full year 2025.

In Q3 2025, BillionToOne’s total revenue was $83.5 million, gross profit was $58.4 million, and operating income was $9.6 million. Net income available to common shareholders was $1.5 million. The company raised $314.0 million in its IPO and holds $195.2 million in cash. Operating expenses were $48.8 million, a 49% increase from Q3 2024.

BillionToOne’s financial outlook is positive, with expectations of strong revenue growth in 2025. The company emphasizes its commitment to scientific rigor and execution. A conference call will be hosted on December 9, 2025, for investors. BillionToOne aims to provide powerful and accessible molecular diagnostics through its innovative technology.

Read more at GlobeNewswire: BillionToOne Reports Third Quarter 2025 Results